共 50 条
- [21] Association of a common genetic variant of the IGF-1 gene with event-free survival in patients with HER2-positive breast cancerJournal of Cancer Research and Clinical Oncology, 2013, 139 : 491 - 498Axel MuendleinAlois H. LangSimone Geller-RhombergThomas WinderKlaus GasserHeinz DrexelThomas DeckerElisabeth Mueller-HolznerMartina ChamsonChristian MarthMichael Hubalek
- [22] Association of a common genetic variant of the IGF-1 gene with event-free survival in patients with HER2-positive breast cancerJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (03) : 491 - 498Muendlein, AxelLang, Alois H.Geller-Rhomberg, SimoneWinder, ThomasGasser, KlausDrexel, HeinzDecker, ThomasMueller-Holzner, ElisabethChamson, MartinaMarth, ChristianHubalek, Michael
- [23] Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trialANNALS OF ONCOLOGY, 2017, 28 (04) : 874 - 881Hui, R.Garon, E. B.Goldman, J. W.Leighl, N. B.Hellmann, M. D.Patnaik, A.Gandhi, L.Eder, J. P.Ahn, M-JHorn, L.Felip, E.Carcereny, E.Rangwala, R.Lubiniecki, G. M.Zhang, J.Emancipator, K.Roach, C.Rizvi, N. A.
- [24] Outcomes and predictive markers of trastuzumab-containing 1st-line chemotherapy in patients with HER2-positive advanced gastric cancerANNALS OF ONCOLOGY, 2017, 28Cheon, J.Ryu, M-H.Park, S. R.Ryoo, B-Y.Jeong, J.Park, J. H.Kim, B.Park, Y.Kang, Y-K.
- [25] Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: of response by line of therapyANNALS OF ONCOLOGY, 2020, 31 : S472 - S473Liu, S. V.De Braud, F.Drilon, A.Doebele, R. C.Patel, M. R.Cho, B. C.Ahn, M-J.Chiu, C-H.Farago, A. F.Goto, K.Lee, J.Ohe, Y.Ou, S-H. I.Cassier, P.Tan, D. S. W.Otterson, G. A.Veronese, L.Osborne, S.Simmons, B.Siena, S.
- [26] ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor-Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor TherapyFRONTIERS IN ONCOLOGY, 2020, 10Reinert, TomasRamalho, SusanaAntunes de Vasconcelos, Vivian CastroSilva, Leonardo RobertoRibeiro da Silva, Ana Elisade Andrade, Camila Annicchinode Paula Leite Kraft, Maria BeatrizCoelho, Guilherme PortelaMandelli, JovanaBinotto, MoniqueCabello, Cesarde Paiva Silva, Geisilene RussanoBines, JoseBarrios, Carlos H.Ellis, Matthew J.Graudenz, Marcia Silveira
- [27] PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offsCANCER RESEARCH AND TREATMENT, 2020, 52 (03): : 661 - 670Park, YujunKoh, JiwonNa, Hee YoungKwak, YoonjinLee, Keun-WookAhn, Sang-HoonPark, Do JoongKim, Hyung-HoLee, Hye Seung
- [28] Potentiation of cytotoxicity against a CEA positive cell line by the bispecific antibody OH1 using LAK cells from cancer-bearing patientsONCOLOGY REPORTS, 1998, 5 (05) : 1141 - 1146Baba, MHideshima, TYamashita, YShirakusa, T
- [29] Cost Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients With Advanced ALK-Positive Non-Small-Cell Lung CancerJOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (10) : 1012 - +Djalalov, SandjarBeca, JaclynHoch, Jeffrey S.Krahn, MurrayTsao, Ming-SoundCutz, Jean-ClaudeLeighl, Natasha B.
- [30] Impact of the Oncotype DX breast cancer assay on treatment decisions in a UK population of patients with oestrogen receptor positive early breast cancer with 1-3 lymph nodes positive who are candidates for chemotherapy, but for whom the benefits are uncertain - Interim resultsCANCER RESEARCH, 2020, 80 (04)Thomas, DanielMaxwell, WilliamArcher, CarolineRigg, AnneHickish, TamasDent, JoPettit, LauraDillon, MarianneGoldsmith, ChristyVerrill, MarkBarthelmes, LudgerKhawaja, SairaSharaiha, YousefDavies, MarkArikat, FawazKhan, SahailMunir, AsmaHuws, AnitaHolt, Simon DavidHenry